Forest Laboratories, Inc. and Nabriva Therapeutics have entered into an agreement for the development of Nabriva’s antibacterial agent, BC-3781. Forest will provide $25 million and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 for the next 12 months, during which Forest has the exclusive right to acquire Nabriva. The transaction is subject to customary regulatory clearances.